Α female patient showed rejection of a Tlymphocyte-depleted bone-marrow graft from her phenotypically HLA-identical father. Before bone-marrow transplantation, there was strong recipient anti-donor cellular cytotoxic reactivity directed against several minor histocompatibility (mH) antigens, including the male-specific H-Y antigen. After conditioning treatment, no recipient anti-donor cytotoxic activity could be detected, and good graft function was shown a month after transplantation. Thereafter, however, graft function deteriorated rapidly, while recipient-derived anti-donor cellular cytotoxic reactivity, against similar mH antigens, reappeared. The recipient-derived cytotoxic Τ lymphocytes could completely inhibit growth of donor haemopoietic progenitor cells both before and after bone-marrow transplantation. Thus, cytotoxic Τ lymphocytes can survive very intensive conditioning regimens, and residual recipient cytotoxic Τ lymphocytes directed against mH antigens expressed on donor haemopoietic progenitor cells may cause graft rejection after HLA-identical T-lymphocyte-depleted bonemarrow transplantation.
Lancet 1990, 335 131-34 introduction T-lymphocyte depletion of bone-marrow grafts has been successfully used to reduce the uicidence of graft-versushost-disease after allogeneic HLA-identical bone-marrow transplantation 1 However, this procedure has resulted in a higher rate of graft failure 2 5 The mechamsms of graft failure have not been elucidated, though failure may be due to immune-mediated rejection of the graft caused by residual lmmvmocompetent reapient cells that have survived the pretransplant conditioning regimen
We report here the detailed analysis of graft rejection in a female bone-marrow transplant recipient of a Tlymphocyte-depleted graft from her phenotypically HLAldenacal father.
Case-report
4 years before bone-marrow transplantanon, this 32-year-old woman was treated for Hodgkin lymphoma (rmxed cellularity, climcal stage IIIB) with radianon therapy and courses of chemotherapy Α complete remission was obtained 3 years later, persisting pancytopema developed and she required red-cell and platelet transfusions Α sample of bone marrow showed a myelodysplastic syndrome (refractory anaenua with excess of blasts, FAB type III) 6 Cytogenetic analysis of bone marrow and blood showed a normal female karyotype Dunng the year before transplantaoon there were repeated hfe-threatemng infections with Pseudomonas aeruginosa, and connnuous intravenous antibiotic treatment was required We decided to carry out allogeneic bone-marrow transplantation with a graft donated by her phenotypically HLA-idenücal father The bone-marrow graft was depleted of Τ lymphocytes by means of munne monodonal antibodies (anti-CD5 and anti-CD8) and baby rabbit complement After depletion, the graft contained 20 x 10 6 nucleated cells and 0 9 x 10 6 CD3-positive cells per kg body weight The conditioning regimen for transplantanon consisted of total body Irradiation (Single dose 9 Gy, dose rate 22 cGy/min, with lung shielding to a cumulanve dose of 6 Gy, additional shielding of the left kidney to a cumulaave dose of 3 Gy) on day -8 before bone-marrow transplantanon, and cyclophosphamide (60 mg/kg daily) on days -5 and -4 Since her nsk of graft rejecnon was thought to be high because of pretransplant sensmsanon, the patient was treated with horse annthymocyte globuhn (ATG, Upjohn, Kalamazoo) 20 mg/kg daily, intravenously on days -3, -2, -1, and on the day of transplantation (day 0) ATG was continued at a dose of 5 mg/kg daily every 2 days after transplantation unul day +12 Methylprednisolone (10 mg/kg daily) was given from day -5 to day + 12 Cyclosponn (3 mg/kg daily by connnuous Infusion) was started on day -1 and continued to day + 14 From that nme onwards, cyclosponn was given orally at a dose of 3 mg/kg, three tunes a day Engraftment was noted on day + 20, and good graft function was documented on day +36 (neutrophils 9 χ lO^l, renculocytes 50 per 1000) After day +43, graft funcnon detenorated, resulting in complete pancytopema on day +64 On day + 85 leukaemic cells were observed in the penpheral blood and bone marrow The patient's condinon thereafter detenorated rapidly and she died 105 days after bone-marrow transplantation heat-inacnvated human AB serum After 6 days of culture, responder cells were harvested and used in a cell-mediated lympholysis assay' Alternatively, responder cells were expanded by resnmulanon with 10 6 lrradiated (20 Gy) mononuclear cells or irradiated (50 Gy) Epstein-Barr-virus (EBV) transformed Β cells from the donor (5 χ 10 5 cells per 10 s responder cells) in RPMI with 20% T-cell growth factor (Biotest, Offenbach, West Germany) plus 15% serum Fresh medium was added every 3 or 4 days and new stimulator cells were added once a week In this way, prohferating cell lines were established that could be kept in culture for many weeks Cytotoxic reacüvity was tested in a chromium-51-release assay 7 Surface marker analysis with monoclonal anübodies against CD3, CD4, CD8, or CD16 anngens was carned out as descnbed previously 8 Cell-mediated cytotoxicity against haemopoienc progerutor cells was mvesogated as descnbed previously 9 Bnefly, 5 x 10 5 effector cells were incubated with "5 x 10* bone-marrow mononuclear cells in 0 5 ml medium (RPMI 1640 plus 15% serum) for 4-18 h Thereafter, the cell mixiure was washed once in RPMI plus 15% serum and cultured for the myeloid (CFU-GM), erythroid (CFU-E/BFU-E), and the multipotent (CFU-GEMM) haemopoietic progemtor cells The percentage growth in these cultures was calcula £ed as the ratio of colorues grown in the presence of effector cells to colorues observed in untreated control cultures
Results
The paotnt and her father had identical HLA phenotypes, as defined by serological assue typrng techniques Typing of other ianuly members showed that the patient had inhented the AI, B8, Bw6, Cw7, DR3, DQw2 haplotype from her mother and shared the A2, Bw61, Bw6, Cw2, DR4, DQw3 haplotype with her father There was no reactivity in crossmatches between leucocytes, platelets, and erythrocytes from the recipient and serum from the donor or the opposite combinaaons However, there was streng recipient ann-donor reactivity in both the rmxed lymphocyte reaction (relative response mdex 78%) and the cell-mediated lympholysis assay, no donor anti-recipient reactivity was observed By means of a panel of target cells, we showed that the anü-donor cytotoxic T-lymphocyte hne estabhshed from the recipient before transplantaaon had cytotoxic reactivity against several minor histocompanbihty (mH) antigens, including the male-specific antigen H-Y (table i), there was substannal lysis of all HLA-Al-posiOve male target cells The male specificity of the cytotoxic T-lymphocyte hne was confirmed by means of a subclone (data not shown) However, substannal lysis of several female target cells was also observed, lndicanng additional cytotoxic reactivity against other mH anügens This reacnvity seemed to be restncted by the HLA A1/B8 or HLA A2 antigens Differential lysis of target cells from pairs of genotypically HLA-idenncal sibhngs confirmed that these reacnvities were directed against mH antigens * Effector/target ratio 10/1 tBone marrow from a female donor whose phytohaemagglutimn stimulated blasts were not lysed in the "Cr-release assay Chromosome analysis 10 of recipient bone marrow and peripheral blood cells after bone-marrow transplantation is presented in table π. During the first 60 days only donor-type metaphases could be detected, whereas from day 88 onwards there was progressive loss of cells with donor-type metaphases. They were replaced by recipienttype cells with normal metaphases and leukaemic cells with an XO karyotype. The latter cells were also of recipient origin as shown by chromosome polymorphism.
After total body irradiation 6 days before transplantation anti-mH reacüvity was still found (table II) on Stimulation of recipient mononuclear cells with irradiated donor mononuclear cells. No anti-donor lymphocyte lines could be generated from the recipient on days -4, -1, +8, + 12, + 15, or +21. However, from day +28 to day +105, T-lymphocyte lines could be established from the recipient after specific Stimulation with donor cells (table II) . Specific anti-donor cytotoxicity was observed on days + 64, + 88, + 96, and + 105. All these lines were of recipient origin, as shown by their normal 46XX karyotype on chromosome analysis.
Α comparison of the cytotoxic reactivity of T-lymphocyte lines established before and after transplantation is shown in table III. HLA-restricted anti-mH reactivity could be shown both before and after transplantation. The cytotoxic reactivity patterns obtained before and after transplantation were similar, although there were some differences in HLA-A2-restricted anti-mH reactivity (table in) .
There was strong inhibition of donor CFU-GM, CFU-E, BFU-E, and CFU-GEMM colony growth on incubation with anti-donor cytotoxic T-lymphocyte lines established before and after transplantation, whereas no such inhibition was observed with haemopoietic progenitor cells from an unrelated individual. Thus, the cytotoxic reactivity of the recipient cells against donor haemopoietic progenitor cells was antigen specific (table iv).
Discussion
We have investigated the mechanism of graft failure in a patient who underwent T-lymphocyte-depIeted bonemarrow transplantation. During pretransplant analysis this patient was found to be immunised against several mH antigens. Anti-mH activity was still detectable after total body irradiation, but it disappeared after completion of the immunosuppressive conditioning regimen. Good graft function was demonstrated about a month after transplantation, and routine cytogenetic analysis at this time showed only donor-type metaphases. However, even during this period of good engraftment of donor cells, Tlymphocyte lines of recipient origin could be established after specific in-vitro Stimulation with donor cells. At first this anti-donor response was merely proliferative. However, at the time of clinical graft failure, host-derived cytotoxic Τ lymphocytes were able to lyse donor Τ cells and haemopoietic progenitor cells. Finally, only autologous (host-derived) normal and leukaemic cells were detectable and the patient died.
Cytotoxic T-lymphocyte lines established before and after bone-marrow transplantation showed several anti-mH cytotoxic specificities, including the male-specific H-Y antigen. The cytotoxic reactivity of the effector cells was similar before and after transplantation, although there were some differences in HLA-A2-restricted specificities afterwards. In a previous female patient treated by our group 11 an HLA-restricted H-Y-specific T-cell response from the peripheral blood could be elicited after rapid rejection of an unmodified bone-marrow graft from her genotypically HLA-identical brother. These observations and others 1213 show that immunocompetent cells can survive intensive conditioning regimens. In allogeneic bone-marrow transplantation with undepleted grafts, residual immunocompetent cells in the recipient, capable of rejecting the graft, may be suppressed or eliminated by donor Τ lymphocytes present in the graft. Indeed, the engraftment-promoting effect of Τ lymphocytes has been shown in several animal models. 1415 When the bonemarrow graft is depleted of Τ lymphocytes to prevent graft-versus-host disease, this immunosuppressive effect of donor Τ lymphocytes is also lost, resulting in a greater risk of graft rejection.
"
5 This report shows that prior sensitisation of the recipient against donor antigens may even further raise the risk of graft rejection. 16 We have identified the expression of several mH antigens on haemopoietic progenitor cells and shown that they can be recognised by cytotoxic Τ lymphocytes as possible target structures. Since mH antigens seem to be differentially expressed on haemopoietic progenitor cells, 17 not all mH antigens may be equally important in bone-marrow graft rejection. The recipient cytotoxic Τ lymphocytes directed against mH antigens in our patient before and after transplantation could completely inhibit growth of donor haemopoietic progenitor cells; this anti-mH reactivity was therefore the cause of the graft rejection.
In conclusion, this study has shown that it may not be possible to eradicate all immunocompetent cells in recipients of bone-marrow transplantation, even with highly immunosuppressive conditioning regimens. Furthermore, complete chimerism, as determined by cytogenetic analysis of bone marrow and peripheral blood cells after transplantation, does not exclude the presence of residual immunocompetent recipient Τ cells capable of graft rejection. These recipient Τ cells can be detected in vitro by specific Stimulation with donor cells. Finally, cytotoxic Τ cells against mH antigens that are present before bonemarrow transplantation can be directly involved in the rejection of HLA-identical bone-marrow grafts. Pretransplant immunisation, for example by blood transfusions, may be an important factor in this process.
